YSP Good Proxy to Domestic Drug Industry (Malaysia)
This article was originally published in PharmAsia News
According to estimates by Kenanga Investment Bank Research, YSP Southeast Asia Holding may be a legitimate proxy for the Malaysian pharmaceutical industry. In the first half of 2007, the company saw its pretax profits double, thanks to a 15 percent increase in sales, most of which came from exports. The majority of YSP's products are produced in Malaysia, at a facility in Selangor. It also boasts several distribution centers around the country. As a subsidiary of Yung Shin Pharmaceutical Industries in Taiwan, YSP has greater access to research and development then many of its competitors. These factors will allow YSP to further increase its exports, providing access to a market beyond Malaysia's population of 24.8 million. The company plans to expand exports throughout its distribution network in the Philippines, Singapore, Vietnam, Myanmar, and Cambodia. (Click here for more
You may also be interested in...
Results from two trials confirm patients at high risk of bleeding treated with Abbott’s Xience stent can be safely treated with short regimens of dual antiplatelet therapy.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance hopes to build a potentially best-in-class presence in a competitive landscape.
An expert panel at the virtual HLTH conference discussed the role of robotics in improving health and wellness in the health continuum. See what Darla Hutton, vice president of US marketing and customer hospital analytics at Intuitive Surgical, said about the future of robotics.